Synthesis and Antitumor Evaluation of Biotin-SN38-Valproic Acid Conjugates.

Yi Dai, Yang Zhang, Tianxiang Ye, Yue Chen

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

The Conjugation of Paclitaxel with Chalcones for Enhancing Anti-tumor Activity.Current organic synthesis · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yi DaiCollege of Pharmaceutical Science, Anhui Xinhua University, Hefei 230088, China.

Yang ZhangDepartment of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230031, China.

Tianxiang YeCollege of Pharmaceutical Science, Anhui Xinhua University, Hefei 230088, China.

Yue ChenCollege of Pharmaceutical Science, Anhui Xinhua University, Hefei 230088, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the strong anticancer activity of SN38 (7-ethyl-10-hydroxy-camptothecin), the severe side effects and loss of anticancer activity caused by the lack of selectivity to cancer cells and hydrolysis of ring E prevent its clinical application. To address the issue, herein a multifunctional SN38 derivative (compound

Indexed as

Antineoplastic Agents, PhytogenicValproic AcidAnimalsBiotinCamptothecinCell Line, TumorFibroblastsHeLa CellsHumansIrinotecanMiceNIH 3T3 CellsAntineoplastic Agents, PhytogenicBiotinCamptothecinIrinotecanValproic Acid7-ethyl-10-hydroxy-camptothecinanticancerbiotinconjugatesynthesisvalproic acid

Identifiers

PMID37175346

DOI10.3390/molecules28093936

PMCPMC10179906

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.